Details for Patent: 11,701,330
Which drugs does patent 11,701,330 protect, and when does it expire?
Patent 11,701,330 protects EPIDIOLEX and is included in one NDA.
This patent has fifty-five patent family members in eleven countries.
Summary for Patent: 11,701,330
| Title: | Use of cannabinoids in the treatment of epilepsy | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Abstract: | The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs). | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventor(s): | Geoffrey Guy, Stephen Wright, Orrin Devinsky | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assignee: | GW Pharma Ltd , Jazz Pharmaceuticals Research UK Ltd | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Application Number: | US17/472,016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 11,701,330 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Patent Claim Types: see list of patent claims | Use; Composition; | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patent landscape, scope, and claims: | Executive summary: U.S. Patent No. 11,701,330 protects a narrow treatment protocol for cannabidiol in Lennox-Gastaut syndrome (LGS) or Dravet syndrome (DS). The independent claim requires all of the following: a qualifying treatment-resistant epilepsy, a CBD drug substance containing at least 98% CBD, administration beginning at approximately 5 mg/kg/day, dose escalation in approximately 5 mg/kg increments, and liver-function testing. Dependent claims add maximum doses, 10 mg/kg/day and 20 mg/kg/day regimens, synthetic CBD, impurity specifications, seizure-reduction outcomes, and testing at baseline, four weeks, or 12 weeks. The patent does not claim CBD as a chemical compound, a CBD formulation in the abstract, or every use of Epidiolex. Its commercial relevance is concentrated on a labeled or substantially equivalent dosing-and-monitoring protocol for Epidiolex or another highly purified CBD product used in LGS or DS. U.S. Patent 11,701,330 CBD Epilepsy Patent Scope, Claims, Expiration, and Competitive LandscapeWhat does U.S. Patent 11,701,330 protect?The patent protects methods of treating seizures associated with LGS or DS using a highly purified CBD drug substance while monitoring liver function and escalating the dose from approximately 5 mg/kg/day. Claim 1 is the controlling independent claim. A practicing party must satisfy each limitation:
The claim is cumulative. A method that meets the disease, product, and dose requirements but does not include liver-function testing would not literally satisfy claim 1. Conversely, liver testing alone does not create infringement unless the remaining disease, purity, and dosing limitations are also met. The patent is therefore a regimen patent with product-quality limitations. It is not a broad composition-of-matter patent. How do the dependent claims expand the patent’s scope?Claims 2 through 30 divide into five principal groups: dose limits, product purity, clinical outcomes, disease-specific regimens, and liver-function testing schedules. Dose-escalation claimsClaims 2 through 5 cover dose escalation to:
Claims 18 through 25 apply the 10 mg/kg/day and 20 mg/kg/day regimens specifically to LGS and DS. The “about” language gives the claims some numerical flexibility, but it does not eliminate the need to prove that the accused regimen falls within the claim’s dose range. A fixed-dose product administered outside the claimed titration sequence presents a stronger non-infringement position than a product administered at the same endpoint dose through a materially different protocol. Synthetic CBDClaim 6 requires synthetic CBD. It narrows the claim rather than expanding it. A botanical CBD product may fall within claim 1 if it satisfies the other limitations, but it would not satisfy claim 6 solely because it contains at least 98% CBD. The synthetic-CBD limitation may have practical importance for suppliers using chemically synthesized cannabidiol rather than plant-derived cannabidiol. It also separates the patent from claims directed only to botanical extracts or full-spectrum cannabis preparations. Impurity specificationsClaims 7 and 8 impose limits on specified cannabinoids and related compounds:
These claims create a product-testing issue in addition to a treatment-method issue. A potential challenger would need analytical data for the CBD drug substance used in the accused product. Batch-specific certificates of analysis, validated assay methods, and manufacturing specifications would be relevant to both infringement and invalidity disputes. Seizure-reduction outcomesClaims 9 through 17 and claims 19 and 23 address treatment of convulsive seizures, reduction in seizure frequency, and at least a 50% reduction in convulsive seizure frequency compared with a baseline period. The baseline comparison is important. Claims requiring a 50% reduction contain an outcome limitation. In a litigation setting, evidence could include seizure diaries, caregiver reports, clinical records, trial data, or treatment-protocol documents. Claims 9, 10, 12, 13, 15, and 16 do not expressly require a 50% reduction, but claims 11, 14, and 17 do. Liver-function testingClaims 26 through 30 cover testing:
These claims make monitoring conduct a central part of the patent estate. The required testing is not limited in the supplied claims to a specific laboratory analyte, such as alanine aminotransferase or aspartate aminotransferase. The specification and prosecution history would determine how broadly “testing liver function” is construed. How does the patent compare with the FDA-approved Epidiolex regimen?The claimed regimen closely tracks the FDA-approved use of cannabidiol oral solution for seizures associated with LGS or DS. The Epidiolex prescribing information describes a starting dosage of 2.5 mg/kg twice daily, equivalent to 5 mg/kg/day. After one week, the dosage can be increased to 5 mg/kg twice daily, equivalent to 10 mg/kg/day. For LGS and DS, the maximum recommended dosage is generally 10 mg/kg twice daily, equivalent to 20 mg/kg/day. The label also requires liver-function evaluation before treatment and monitoring during treatment, particularly in the presence of valproate or clobazam (U.S. Food and Drug Administration, 2024).
The overlap is commercially significant. A labeled administration of Epidiolex for LGS or DS can align with the disease, dose, and monitoring limitations of the patent. That alignment does not by itself establish infringement because the product’s actual CBD specification, the prescribing conduct, the dose-escalation sequence, and the relevant patent term must also be established. What is the patent’s claim strategy?The patent uses a layered claim structure. Broadest practical layerClaim 1 combines the disease, CBD purity, liver testing, starting dose, and dose escalation. It is the principal enforcement claim. Dose-specific layerClaims 2 through 5 and 18 through 25 preserve protection around the 10 mg/kg/day and 20 mg/kg/day regimens. These claims are commercially important because they correspond to the principal clinical dosing levels for Epidiolex. Product-quality layerClaims 6 through 8 target synthetic CBD and specified impurity profiles. These claims may be harder to assess without access to manufacturing and batch records. Clinical-result layerClaims 9 through 17, 19, and 23 add seizure reduction and, in some cases, a 50% reduction from baseline. These claims may have narrower practical coverage because they require proof of patient outcomes. Monitoring layerClaims 26 through 30 cover liver testing at specific treatment stages. These claims may be relevant to a product label, clinical protocol, pharmacy service, or prescriber instruction that incorporates the monitoring schedule. What patents protect Epidiolex and purified CBD beyond U.S. Patent 11,701,330?Epidiolex protection has historically involved several patent categories:
U.S. Patent 11,701,330 should therefore be analyzed as one component of the Epidiolex estate, not as the complete CBD patent position. A freedom-to-operate review would need to examine the patent family, continuation applications, terminal disclaimers, Orange Book entries, and any separately issued formulation or manufacturing patents. What is the Orange Book status of U.S. Patent 11,701,330?The supplied claim text establishes that the patent contains method-of-use claims, but it does not establish an Orange Book listing, listing date, use code, pediatric exclusivity, patent-term adjustment, or patent-term extension. For an NDA product such as Epidiolex, a method-of-use patent may be submitted for Orange Book listing if it claims an approved method of using the drug. The commercial effect of listing depends on:
An Orange Book listing does not establish patent validity. It creates a regulatory certification and litigation framework under the Hatch-Waxman Act. When does U.S. Patent 11,701,330 lose exclusivity?The expiration date cannot be derived reliably from the issue date alone. U.S. utility patents generally expire 20 years from the earliest effective nonprovisional U.S. filing date, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and applicable priority claims (U.S. Patent and Trademark Office, 2024). For this patent, the decisive term variables are:
The 20-year patent term is distinct from FDA regulatory exclusivity. Epidiolex received orphan-drug exclusivity for the approved LGS and DS indications. Orphan exclusivity generally protects the approved indication for seven years from approval, while patent protection can continue beyond that period. The two forms of exclusivity should not be treated as interchangeable. What Paragraph IV challenges and generic entry risks apply?A generic applicant seeking approval for cannabidiol oral solution could use one of four principal certification positions:
For this patent, a Paragraph IV strategy could target one or more limitations:
The strongest practical non-infringement position would generally involve a proposed label that omits the patented indication or dosing instructions. That strategy is constrained if the generic seeks approval for the same LGS or DS uses and adopts the same labeled titration and monitoring protocol. How strong is the patent estate?The patent has meaningful commercial relevance but a narrower legal perimeter than a composition-of-matter patent.
The patent is more valuable against a generic that copies the Epidiolex indication, dose escalation, and monitoring instructions than against a product with a materially different label or clinical protocol. What litigation and settlement issues should be reviewed?The relevant litigation questions are:
A patent-by-patent review of PACER, the Orange Book, USPTO Patent Center, and FDA listing data is required to attribute a specific Paragraph IV case or settlement to Patent No. 11,701,330. The supplied claims alone do not identify a litigant, case number, settlement date, or entry date. What are the principal commercial scenarios for generic entry?Same-label entryA generic copies the LGS and DS indications and the 5 mg/kg/day starting regimen. This presents the highest direct infringement exposure under claim 1. Carved-out indicationA generic omits LGS, DS, or the patented seizure use from its label. This can reduce method-of-use exposure but may limit the approved market. Alternative dosing protocolA generic uses a different titration schedule or omits the claimed escalation sequence. This may avoid literal infringement but could create regulatory and clinical limitations. Different CBD sourceA generic uses botanical rather than synthetic CBD. This may avoid claim 6 but does not avoid claim 1 if the product still meets the other limitations. Different impurity profileA product outside the claimed impurity thresholds may avoid claims 7 and 8. It would still require analysis under claim 1’s 98% CBD requirement. Key Takeaways
FAQsDoes Patent 11,701,330 cover all cannabidiol products?No. The supplied claims require a treatment method involving LGS or DS, a CBD drug substance containing at least 98% CBD, dose escalation, and liver-function testing. Does synthetic CBD automatically infringe the patent?No. Synthetic CBD is expressly required only by dependent claim 6. A product must also satisfy the limitations inherited from claim 1. Is a 20 mg/kg/day Epidiolex regimen within the patent claims?It can be. Claims 4, 18 through 21, and 22 through 25 expressly address approximately 20 mg/kg/day, subject to the remaining claim limitations. Can a generic avoid the patent by using a different CBD formulation?Not necessarily. A different formulation may avoid a separate formulation patent, but it could still fall within the method claims if it meets the disease, purity, dosing, escalation, and monitoring requirements. Does FDA approval prove infringement of Patent 11,701,330?No. FDA labeling may overlap with the patent, but infringement requires proof that every limitation of an asserted claim is met, either literally or under the doctrine of equivalents. References
More… ↓ |
Drugs Protected by US Patent 11,701,330
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jazz Pharms Res | EPIDIOLEX | cannabidiol | SOLUTION;ORAL | 210365-001 | Sep 28, 2018 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | USE FOR THE TREATMENT OF SEIZURES IN PATIENTS WITH LENNOX-GASTAUT SYNDROME | ⤷ Start Trial | ||||
| Jazz Pharms Res | EPIDIOLEX | cannabidiol | SOLUTION;ORAL | 210365-001 | Sep 28, 2018 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | USE FOR THE TREATMENT OF SEIZURES IN PATIENTS WITH DRAVET SYNDROME | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,701,330
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2015275886 | ⤷ Start Trial | |||
| Australia | 2015275887 | ⤷ Start Trial | |||
| Australia | 2020217417 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
